IP Library › Granted Patent US 10,421,987
Granted Patent B2
US 10,421,987 · App. 16/039,123 · Granted Sep 24, 2019

Methods for increasing mannose content of recombinant proteins

Inventors: Chung-Jr Huang (Newbury Park, CA); Xiaoming Yang (Oak Park, CA)
Assignee: Amgen Inc.
C12P21/005C07K16/00C12N5/0018C07K2317/41C12N2500/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,421,987
App. No.
16/039,123
Granted
Sep 24, 2019
Kind
B2
Abstract

The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.

Claims (27)

1. A method for increasing a high mannose glycoform content of a recombinant protein during a mammalian cell culture process comprising:

establishing a cell culture comprising mammalian cells in a bioreactor with a cell culture media that does not contain mannose;

growing said mammalian cells in a growth phrase with a cell culture media that does not contain mannose;

inducing cell growth-arrest by L-asparagine starvation with a serum-free media that does not contain mannose, followed by perfusion with a serum-free perfusion media that does not contain mannose and having an L-asparagine concentration of 5 mM or less;

initiating and maintaining a production phase in said cell culture by perfusion with a serum-free perfusion media comprising mannose to produce said recombinant protein,

wherein a mannose to total hexose ratio in said serum-free perfusion media is greater than 0 but less than 1.0, wherein said high mannose glycoform content of said recombinant protein is increased compared to a cell culture wherein said cell culture is not subjected to a serum-free perfusion media comprising mannose with a mannose to total hexose ratio greater than 0 and less than 1.0.

2. The method of claim 1 , wherein said serum-free media that does not contain mannose for inducing cell growth-arrest by L-asparagine starvation is a serum-free perfusion media.

3. The method of claim 1 , wherein the concentration of L-asparagine in said serum-free perfusion media having an L-asparagine concentration of 5 mM or less is less than or equal to 4 mM.

4. The method of claim 1 , wherein the concentration of L-asparagine in said serum-free perfusion media having an L-asparagine concentration of 5 mM or less is less than or equal to 3 mM.

5. The method of claim 1 , wherein the concentration of L-asparagine in said serum-free perfusion media having an L-asparagine concentration of 5 mM or less is less than or equal to 2 mM.

6. The method of claim 1 , wherein the concentration of L-asparagine in said serum-free perfusion media having an L-asparagine concentration of 5 mM or less is less than or equal to 1 mM.

7. The method of claim 1 , wherein the concentration of L-asparagine in said serum-free perfusion media having an L-asparagine concentration of 5 mM or less is less than or equal to 0 mM.

8. The method of claim 1 , wherein the concentration of L-asparagine in said cell culture media is monitored prior L-asparagine starvation.

9. The method of claim 1 , wherein the concentration of L-asparagine in said cell culture media is monitored prior L-asparagine starvation.

10. A method for increasing a high mannose glycoform content of a recombinant protein during a mammalian cell culture process comprising:

establishing a cell culture comprising mammalian cells in a bioreactor with a cell culture media that does not contain mannose;

growing said mammalian cells in a growth phrase with a cell culture media that does not contain mannose;

inducing cell growth-arrest by L-asparagine starvation with a serum-free perfusion media that does not contain mannose, followed by perfusion with a serum-free perfusion media that does not contain mannose and having an L-asparagine concentration of 5 mM or less;

initiating and maintaining a production phase in said cell culture by perfusion with a serum-free perfusion media comprising mannose to produce said recombinant protein,

wherein a mannose to total hexose ratio in said serum-free perfusion media is greater than 0 but less than 1.0, wherein said high mannose glycoform content of said recombinant protein is increased compared to a cell culture wherein said cell culture is not subjected to a serum-free perfusion media comprising mannose with a mannose to total hexose ratio greater than 0 and less than 1.0.

11. The method of claim 10 , wherein the concentration of L-asparagine in said serum-free perfusion media having an L-asparagine concentration of 5 mM or less is less than or equal to 4 mM.

12. The method of claim 10 , wherein the concentration of L-asparagine in said serum-free perfusion media having an L-asparagine concentration of 5 mM or less is less than or equal to 3 mM.

13. The method of claim 10 , wherein the concentration of L-asparagine in said serum-free perfusion media having an L-asparagine concentration of 5 mM or less is less than or equal to 2 mM.

14. The method of claim 10 , wherein the concentration of L-asparagine in said serum-free perfusion media having an L-asparagine concentration of 5 mM or less is less than or equal to 1 mM.

15. The method of claim 10 , wherein the concentration of L-asparagine in said serum-free perfusion media having an L-asparagine concentration of 5 mM or less is less than or equal to 0 mM.

16. The method of claim 10 , wherein the concentration of L-asparagine in said cell culture media is monitored prior L-asparagine starvation.

17. The method of claim 10 , wherein the concentration of L-asparagine in said cell culture media is monitored prior L-asparagine starvation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2018
From: HUANG, CHUNG-JR; YANG, XIAOMING
To: AMGEN INC.
Reel/Frame 046783/0590 →
Continuity (4)
Continuation 15285392 · Oct 4, 2016
Continuation 14289943 · May 29, 2014
Provisional Application 61828969 · May 30, 2013
Related Publication 20190002946A1 · Jan 3, 2019
Cited By (1)
US 12,378,517